Search results
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 7 days agoAbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
NBC San Diego· 2 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 6 days agoBy almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant...
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters via Yahoo News· 7 days ago(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 2 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q1 2024 Earnings Call Apr 26, 2024, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks· 2 days agoFree Report) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 1.9% over this ...
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks via Yahoo Finance· 7 days agoAbbVie Inc. ABBV reported adjusted earnings of $2.31 per share for first-quarter 2024, beating the...
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 3 days agoFears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as...
Drugmaker AbbVie expects Humira volume erosion to worsen By Reuters
Investing.com· 7 days agoIts shares were down 2% in morning trade on Friday, after the company forecast U.S. Humira sales...
